Relay drug shows early promise against rare blood vessel diseases Summary: In a mid-stage clinical trial, Relay Therapeutics’ drug candidate zovegalisib demonstrated a 60% response rate in patients with rare vascular anomalies, offering potentially superior safety and efficacy compared to Novartis’ existing treatment, Vijoice. Click to see the full article FDA grants Daiichi Sankyo and […]